- Home
- UCAR vs BGMS Comparison
UCAR vs BGMS Comparison
Compare UCAR & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UCAR | BGMS |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | China | Malaysia |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 5.0M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | UCAR | BGMS |
|---|---|---|
| Price | $0.48 | $0.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 73.4K | 17.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.74 |
| 52 Week High | $4.98 | $6.70 |
Technical Indicators
Market Signals| Indicator | UCAR | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 21.10 | 36.87 |
| Support Level | N/A | $0.74 |
| Resistance Level | $2.17 | $1.12 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 0.67 | 54.96 |
Price Performance
Historical ComparisonAbout UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.